- Federal agenciesMakes Executive Order provisions legally binding, requiring agency compliance.
- Potential benefitMay encourage private investment in domestic pharmaceutical manufacturing and related construction jobs.
- Potential benefitCould strengthen supply chain resilience by reducing reliance on foreign medicine suppliers.
Executive Order 14293 Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Transportation and Infrastructure, for a period to be subsequently determined by the Speaker,…
This bill would give the force of law to Executive Order 14293, titled "regulatory relief to promote domestic production of critical medicines." The text of the bill is short: it codifies the Executive Order so its provisions operate as statutory law.
Progressives emphasize protecting safety and labor standards.
Relative to its intended legislative type, this bill is a concise single-purpose measure that declares Executive Order 14293 shall have the force and effect of law.
This bill would give the force of law to Executive Order 14293, titled "regulatory relief to promote domestic production of critical medicines." The text of the bill is short: it codifies the Executive Order so its provisions operate as statutory law.
Low complexity but substantive regulatory implications and lack of detail make obtaining broad support and surviving Senate process uncertain.
Relative to its intended legislative type, this bill is a concise single-purpose measure that declares Executive Order 14293 shall have the force and effect of law. It provides a clear, narrow mechanism but lacks substantive statutory detail on implementation, fiscal effects, integration with existing law, edge cases, and accountability.
Progressives emphasize protecting safety and labor standards.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenMay lower regulatory safeguards if 'relief' reduces testing, inspection, or approval standards.
- Federal agenciesReduces agency discretion by converting executive directives into binding statutory requirements.
- Potential burdenCould prompt litigation over the scope, interpretation, or constitutionality of codified directives.
Why the argument around this bill splits.
Progressives emphasize protecting safety and labor standards.
Generally supportive of boosting domestic medicine production, but wary of unspecified "regulatory relief." Concerned about safety, access, labor, and environmental protections.
Wants guarantees that relief won’t roll back FDA standards or worker protections.
Cautiously favorable: supports domestic production and supply-security goals but wants targeted, evidence-based regulatory relief.
Seeks oversight, measurable outcomes, and budgetary clarity before strong endorsement.
Likely supportive: favors regulatory relief and domestic manufacturing incentives to reduce dependence on foreign supply chains.
Views codification as stronger, lasting policy than an executive order.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Low complexity but substantive regulatory implications and lack of detail make obtaining broad support and surviving Senate process uncertain.
- Exact substantive provisions of Executive Order 14293
- Absent CBO or cost estimate and fiscal impacts
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize protecting safety and labor standards.
Low complexity but substantive regulatory implications and lack of detail make obtaining broad support and surviving Senate process uncerta…
Relative to its intended legislative type, this bill is a concise single-purpose measure that declares Executive Order 14293 shall have the force and effect of law. It provides a clear, narrow mechanism but lacks substa…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.